Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Dicerna Pharmaceuticals Inc (DRNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/28/2021 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Second Amended and Restated Certificate of Incorporation",
"Second Amended and Restated By-Laws",
"Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition LEXINGTON, Mass.—— Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. , announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021, which represent approximately 82.6..."
11/18/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, by and among Dicerna Pharmaceuticals, Inc., Novo Nordisk A/S, and NNUS New Research, Inc.",
"Novo Nordisk to Acquire Dicerna"
11/09/2021 8-K Quarterly results
Docs: "Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update – Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria –"
08/09/2021 8-K Quarterly results
Docs: "Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update – Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria –"
08/06/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria – Nedosiran Achieved Primary Endpoint, Demonstrating Statistically and Clinically Significant Sustained Reduction in Urinary Oxalate Excretion&#59; Key Secondary Endpoint Also Achieved&#59; Robust Efficacy Seen in PH1 Participants –",
"Topline Data Presentation Investigation of Nedosiran for the Treatment of Primary Hyperoxaluria Type 1 and Type 2 August 5, 2021"
06/04/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/12/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
01/12/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update – Company Targeting Enrollment Completion for Pivotal PHYOX™2 Trial of Nedosiran in Fourth Quarter 2020 –"
10/22/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria – All Participants Receiving Nedosiran, Regardless of Subtype, Achieved Normalization or Near-Normalization of Urinary Oxalate, a Key PH Measure, by Day 180 in Ongoing, Open-Label Trial –"
09/16/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Dicerna Appoints Ling Zeng as Chief Legal Officer and Secretary – Biopharmaceutical Industry Veteran Brings Expertise in Global Drug Development and Corporate Governance –"
09/14/2020 8-K Quarterly results
08/12/2020 8-K Quarterly results
08/11/2020 8-K/A Quarterly results
08/06/2020 8-K Quarterly results
07/08/2020 8-K Quarterly results
06/18/2020 8-K Quarterly results
06/16/2020 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
Docs: "DICERNA PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY"
05/08/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
04/20/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/06/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs"
04/01/2020 8-K Quarterly results
03/31/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Dicerna Provides Initial Observations From PHYOX™3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria (PH) and Update on Data Presentation Plan"
03/26/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
02/10/2020 8-K Quarterly results
02/06/2020 8-K Other Events
01/13/2020 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Form of Restricted Stock Unit Award Agreement",
"Form of Restricted Stock Unit Grant Notice",
"Dicerna Pharmaceuticals, Inc. corporate presentation"
12/16/2019 8-K Resignation/termination of a director
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy